LOGIN  |  REGISTER
Chimerix

Viemed Healthcare Announces Date and Time for Conference Call

April 23, 2024 | Last Trade: US$8.02 0.00 0.00

LAFAYETTE, La., April 23, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Tuesday, May 7, 2024 at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)
+1 201-689-8451 (International)

Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. by 12:00 p.m. ET Monday, May 6, 2024.

Live Audio Webcast Link

Following the live call, a replay will be available in the Investor Relations section of the Company’s website, www.viemed.com

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com

For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it.

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB